Imcyse plans first human trial of disease-modifying MS vaccine
This article was originally published in Scrip
Executive Summary
Belgium start-up Imcyse believes it has a promising candidate for a disease-modifying multiple sclerosis vaccine. The company is planning a first-in-human study of the product in September, it told Scrip.